Kymera Therapeutics Inc. (KYMR) News
Filter KYMR News Items
KYMR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KYMR News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest KYMR News From Around the Web
Below are the latest news stories about KYMERA THERAPEUTICS INC that investors may wish to consider to help them evaluate KYMR as an investment opportunity.
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 14, 2025, at 9:00 a.m. PT/12:00 p.m. ET. Nello Mainolfi, PhD, Founder, President and CEO, will |
Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken dealLeerink keeps an Outperform rating and a $60 price target on Kymera Therapeutics (KYMR) while noting that the firm sees a “positive readthrough” from the J&J’s (JNJ) in-licensing of an oral STAT6 program from Kaken Pharmaceutical. Kymera has recently started a Phase 1 for STAT6 degrader KT-621, while JNJ announced an in-licensing deal with Japan-based Kaken Pharmaceutical for small molecule STAT6 program KP-723, and while there are limited data publicly available about KP-723, the deal serves as |
Kymera Therapeutics to Participate in Upcoming December Investor ConferencesWATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: Piper Sandler 36th Annual Healthcare Conference in New York, NY on December 3 at 1:00 p.m. ET; and7th Annual Evercore ISI HealthCONx Conference in Coral Gables, |
Kymera Therapeutics to Participate in Upcoming November Investor ConferencesWATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: Guggenheim Inaugural Healthcare Innovation Conference in Boston, MA on November 12 at 10:00 a.m. ET;J.P. Morgan Equity Opportunities Forum in Miami, FL on Novem |
Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter ReportLast week, you might have seen that Kymera Therapeutics, Inc. ( NASDAQ:KYMR ) released its quarterly result to the... |
Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagKymera Therapeutics ( NASDAQ:KYMR ) Third Quarter 2024 Results Key Financial Results Revenue: US$3.74m (down 21% from... |
Kymera Q3 Loss Narrower Than Expected, Pipeline in FocusKymera reports a narrower-than-expected loss in the third quarter. The company expects the current cash balance to provide a runway into mid-2027. |
Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...Kymera Therapeutics Inc (KYMR) showcases promising clinical progress and robust financial health, despite facing competitive challenges and strategic shifts. |
U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain PartnersU.S. drugmakers and biotechs have come to rely on Chinese partners. Now, some of them are looking for alternatives as geopolitical tensions rise. |
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue EstimatesKymera Therapeutics (KYMR) delivered earnings and revenue surprises of 1.20% and 58.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |